Published in Eur J Clin Pharmacol on June 18, 2013
Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life (2015) 0.79
Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med (2003) 8.33
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med (1997) 4.47
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19
Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev (2009) 2.16
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics (1997) 1.57
Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci (2004) 1.52
Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res (2006) 1.43
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40
The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol (2008) 1.26
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
The influence of age on the response to anticoagulants. Br J Clin Pharmacol (1977) 1.07
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J (2011) 1.07
Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet (2008) 1.05
CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther (2004) 1.03
The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Haematol (2006) 1.02
The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics (2004) 1.00
In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther (1998) 0.99
Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol (2009) 0.91
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
A novel, single algorithm approach to predict acenocoumarol dose based on CYP2C9 and VKORC1 allele variants. PLoS One (2010) 0.85
Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol (2011) 0.84
Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabol Drug Interact (2012) 0.82
An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One (2012) 0.82
No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol (1997) 0.81
Drug metabolism in the elderly. Pharmacol Ther (1988) 0.81
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med (2012) 0.77
Effect of age and sex on acenocoumarol requirements. Br J Clin Pharmacol (1984) 0.75
Lack of effect of omeprazole in oral acenocoumarol anticoagulant therapy. Scand J Gastroenterol (1997) 0.75
The use of ultrasonography in learning clinical examination - a pilot study involving third year medical students. Med Ultrason (2012) 1.51
Using ultrasonography as a teaching support tool in undergraduate medical education - time to reach a decision. Med Ultrason (2012) 0.93
Ethical views, attitudes and reactions of Romanian medical students to the dissecting room. Rev Med Chir Soc Med Nat Iasi (2015) 0.81
Association of 276G>T adiponectin gene polymorphism to plasma adiponectin and albuminuria in type 2 diabetic patients. Int Urol Nephrol (2012) 0.78
PAI-1 4G/5G and MTHFR C677T polymorphisms increased the accuracy of two prediction scores for the risk of acute lower extremity deep vein thrombosis. Rom J Morphol Embryol (2014) 0.78
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med (2012) 0.77
The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis (2012) 0.77
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis. Dermatology (2015) 0.76
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis. Immunol Lett (2013) 0.76
UHPLC/PDA-ESI/MS analysis of the main berry and leaf flavonol glycosides from different Carpathian Hippophaë rhamnoides L. varieties. Phytochem Anal (2013) 0.75
First year medical students' attitude toward anatomical corpse dissection and its relationship with their personality. Rom J Morphol Embryol (2015) 0.75
JAK2 46/1 haplotype seems not to be associated with lower limb deep venous thrombosis. Blood Cells Mol Dis (2010) 0.75
Autoimmune hepatitis with sclerosing cholangitis in a patient with thiopurine methyltransferase deficiency: case presentation. Rom J Morphol Embryol (2017) 0.75
Disease activity and disability evolution under glatiramer acetate: a clinical approach. Neuropsychopharmacol Hung (2014) 0.75
Deep vein thrombosis--online methods of patient education. Med Ultrason (2010) 0.75
Paraoxonase 1 genotype-phenotype correlation in patients with metabolic syndrome. Rom J Morphol Embryol (2015) 0.75